Open-market purchases of Scribe Therapeutics Inc. (SCTX) stock by its own executives, directors and 10% owners — every Form 4 buy of $250K or more that SPX Lens's daily insider scan has recorded, newest first.
| Scan | Insider | Value | Type | |||
|---|---|---|---|---|---|---|
| Jul 30, 2026 | Carl L. GordonDirector | $15.0M | New stake | |||
| IPO purchase at $15.00/share; SCTX now $18.36 (+22.4% since buy). Gordon is a Partner at OrbiMed Advisors; companion Form 4 also filed by OrbiMed Advisors LLC (accession 0000947871-26-000733) for the same transaction. Part of a $56M+ cluster buy at the SCTX IPO alongside Avoro/Aghazadeh ($36M, filed July 28) and Andreessen Horowitz ($5M). | ||||||
| Jul 30, 2026 | Marc L. Andreessen10% Owner / Venture Investor (Andreessen Horowitz) | $5.00M | New stake | |||
| IPO purchase at $15.00/share via AH Bio Fund II, L.P.; filing also names Ben Horowitz. SCTX now $18.36 (+22.4% since buy). a16z also received 2,749,392 shares from preferred-stock conversions (AH Bio Funds II & III). Stock ran to $22.31 on first trading day before pulling back to $18.36. | ||||||
| Jul 29, 2026 | Behzad Aghazadeh / Avoro Capital Advisors LLC / Avoro Ventures LLCDirector / 10% Owner | $36.3M | New stake | |||
| IPO allocation of 2,333,333 shares at $15.00 ($35.0M from underwriters, ~July 24 IPO) plus post-IPO open-market: 50,000 shares at $22.31 and 7,905 shares at $18.25. Current price $18.06 (+20.4% vs IPO price; -17.7% vs avg open-market buy of ~$21.93). Gene-editing / CRISPR biotech; Aghazadeh sits on board. | ||||||
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.
Open the live chartOpen in the Stocks tab© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.